InvestorsHub Logo
Followers 42
Posts 4186
Boards Moderated 0
Alias Born 01/04/2017

Re: Nick119 post# 372096

Saturday, 04/24/2021 7:23:46 AM

Saturday, April 24, 2021 7:23:46 AM

Post# of 716897
I really liked this part also:

The New Jersey pharma has been under investor pressure to diversify its portfolio beyond what’s soon to be the world’s best-selling drug—its immuno-oncology therapy Keytruda. The company did strike several deals recently when incoming CEO Rob Davis was behind the M&A wheel as chief financial officer. It unveiled just two months ago a $1.85 billion transaction for Pandion Therapeutics.

During the company’s fourth-quarter earnings call, Davis said the company would still be looking at “smaller opportunities where we can find great science earlier in its life” and will not rule out larger-scale deals.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News